Dexmethylphenidate controlled release - Cingulate Therapeutics
Alternative Names: CTX-1301; Dexmethylphenidate HClLatest Information Update: 02 Jun 2025
At a glance
- Originator Cingulate Therapeutics
- Developer Bio-Images Drug Delivery; Cingulate Therapeutics
- Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Attention-deficit hyperactivity disorder
Most Recent Events
- 20 May 2025 Cingulate Therapeutics announces its intention to launch CTX 1301 with a total of eight dosage strengths, six of which are expected to treat patients under the age of 18
- 20 May 2025 Efficacy data from a phase III trial in Attention-deficit hyperactivity disorder released by Cingulate Therapeutics
- 02 Apr 2025 Cingulate Therapeutics hold a pre-NDA meeting with the US FDA for New drug application submission for Dexmethylphenidate